DELFI Diagnostics Inc, a California-based developer of innovative blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer detection and monitoring, said on Monday that its chief technology officer (CTO), Dr Amoolya Singh, has been named in the San Francisco Business Times' 2025 Most Influential Women in Bay Area Business list.

Dr Singh, who was previously named to this list in 2021, joined DELFI in December 2024 and has over two decades of experience working at the intersection of biotechnology and computational science. She has an track record of developing breakthrough genomic technologies and products. As the CTO of DELFI Diagnostics, she leads the company's strategic technology roadmap to help deliver reliable, affordable and non-invasive tests that enhance cancer detection and transform how cancer is diagnosed and treated, particularly for high-risk patients in underserved communities.

The San Francisco Business Times' annual Most Influential Women in Bay Area Business list aims to recognise exceptional business leaders making significant contributions to their companies, industries and communities. Dr Singh was selected from nearly 400 nominees.

"Amoolya excels at integrating biology and assay with computational science and software, and combines her technical skills with a collaborative approach to leadership that ensures her teams can work together to push the boundaries of science and technology and ultimately, revolutionise healthcare," said Susan Tousi, DELFI Diagnostics CEO. "We're proud of this recognition and that she's part of our team of experts working to improve the accuracy and accessibility of cancer screening."

"I'm honoured to be listed among these notable leaders in Bay Area business," added Dr Singh. "I am passionate about people and science, and my focus will always remain on making an impact in my work, while ensuring it serves others. I believe strongly in DELFI's mission, and I am excited to advance its groundbreaking research further and reduce it to practice."